VIB7734

DRUG3 trials

Sponsors

Amgen, Viela Bio

Conditions

Acute Lung InjuryCutaneous Lupus ErythematosusDermatomyositisLupus Erythematosus, SystemicPolymyositisSjogren's SyndromeSystemic Lupus ErythematosusSystemic Sclerosis

Phase 1

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

CompletedNCT03817424

AmgenCutaneous Lupus Erythematosus, Dermatomyositis, Polymyositis +3

Start: 2018-12-13End: 2020-07-20Updated: 2024-12-13

Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

TerminatedNCT04526912

Viela BioAcute Lung Injury

Start: 2020-08-28End: 2021-05-19Updated: 2021-12-17

Phase 2

Study of VIB7734 for the Treatment of Moderate to Severely Active SLE

CompletedNCT04925934

AmgenLupus Erythematosus, Systemic

Start: 2021-05-28End: 2023-06-09Updated: 2024-07-23